<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941550</url>
  </required_header>
  <id_info>
    <org_study_id>13-005</org_study_id>
    <nct_id>NCT01941550</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy With Cabazitaxel</brief_title>
  <acronym>CLUBNET</acronym>
  <official_title>Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at evaluating the efficacy regarding the response rate and&#xD;
      metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with high&#xD;
      risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated by 6 cycles of Cabazitaxel 25 mg/m2 every three weeks and extended&#xD;
      radical prostatectomy and extended pelvic lymphadenectomy 4 weeks after completion of&#xD;
      chemotherapy. Multiparametric MRI will be performed at baseline, after 3 cycles and after 6&#xD;
      cycles. If there will be evidence of clinical progression after 3rd cycle, patients can be&#xD;
      removed from the study and given local therapy, including radical prostatectomy or external&#xD;
      beam radiotherapy, at the discretion of the patient's physicians. If patients have evidence&#xD;
      of response, they continue on treatment for a total of 6 cycles. If multiparametric MRI&#xD;
      demonstrates stable disease an individual risk-benefit analysis has to be performed with&#xD;
      regard to continuing or to stopping the neoadjuvant treatment since the definition stable&#xD;
      disease includes patients with ≤ 20% tumour shrinkage or tumour progression&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left the site. Site closed.&#xD;
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete pathological response rate</measure>
    <time_frame>5 years</time_frame>
    <description>Primary endpoint: overall or cancer specific survival nor progression-free survival(PFS) in 5 years. Composite measurement.&#xD;
Key-parameters:&#xD;
Complete pathohistological remission&#xD;
Intra/perioperative compl.&#xD;
PFS&#xD;
Metastasis-FS&#xD;
Biochemical, radiological, clinical PFS and androgen-deprivation FS&#xD;
Objective progr. during cabazitaxel therapy (cab.th.) and post surgery&#xD;
PSA response at the end of cab.th.&#xD;
PSA progression after 12 w. of cab.th.&#xD;
Percentage of pat. with undetectable PSA (&lt;0.1 ng/ml) post surgery&#xD;
Relationship between PSA kinetics, histol. response and MRI response&#xD;
Role of pathohistol. parameters such as intraductal, cribriform growth patterns and effect on response&#xD;
Immunohistochemical evaluation of prostate biopsy and radical prostatectomy specimens of markers potentially associated with chemoresistance: growth differentiation factor 15, surviving, beta-tubuline I &amp; II, p53, bcl-2,&#xD;
Measurement of the serum concentrations of free circulating mDNA</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>High-Risk Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.&#xD;
For max. 6 times at all.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel chemotherapy</intervention_name>
    <description>given in 6 cycles</description>
    <arm_group_label>Cabazitaxel chemotherapy</arm_group_label>
    <other_name>Jevtana L01CD04</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Surgically resectable high risk prostate cancer with a 5-year relapse probability ≥&#xD;
             60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010)&#xD;
&#xD;
               -  no prior therapy for prostate cancer such as androgen deprivation therapy,&#xD;
                  radiation therapy, or chemotherapy&#xD;
&#xD;
               -  ECOG performance status 0-1&#xD;
&#xD;
          -  No evidence of active infection&#xD;
&#xD;
               -  Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1.5 x 109/L,&#xD;
&#xD;
               -  Platelet count &gt;100 x 109/L,&#xD;
&#xD;
               -  AST/SGOT and/or ALT/SGPT &lt;2.5 x ULN;&#xD;
&#xD;
               -  Total bilirubin &lt;1.0 x ULN,&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance&#xD;
                  will be calculated according to CKD-EPI formula and patients with creatinine&#xD;
                  clearance &lt;60 mL/min should be excluded)&#xD;
&#xD;
               -  Patient information and signature of informed consent&#xD;
&#xD;
               -  Male ≥ 18 years&#xD;
&#xD;
               -  Patients of reproductive age must take appropriate contraceptive precautions&#xD;
                  during and for 6 months after the end of their participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of lymph node, visceral or bone metastases&#xD;
&#xD;
               -  previous major intrapelvic surgery&#xD;
&#xD;
               -  previous radiation therapy to the small pelvis&#xD;
&#xD;
               -  any type of malignancies within the last 5 years except basalioma and non-muscle&#xD;
                  invasive urothelial cancer of the urinary bladder&#xD;
&#xD;
               -  previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any&#xD;
                  indication&#xD;
&#xD;
               -  Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
               -  Known or suspected brain metastases or leptomeningeal metastases&#xD;
&#xD;
               -  Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
               -  Serious or uncontrolled co-existent non-malignant disease, including active and&#xD;
                  uncontrolled infection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated, high risk prostate cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

